Established in 1988 and headquartered in Leeds, United Kingdom, Surgical Innovations Group plc is an international enterprise engaged in the design, development, manufacturing, and marketing of devices for minimally invasive surgery (SI) and precision engineering applications. Its global presence extends across the UK, Europe, the Asia Pacific region, and the United States. The company operates through three distinct divisions: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The SI Brand segment is responsible for the research, development, production, and commercialization of its proprietary SI-branded minimally invasive instruments. Key products within this portfolio include the YelloPort Elite and YelloPort +plus laparoscopic port access systems, LogiRange resposable laparoscopic instrument systems, FastClamp laparoscopic clamping systems, and QuickRange single-use laparoscopic instrumentation. The OEM division focuses on crafting and supplying minimally invasive devices for third-party medical device firms, often under their own brand or through co-branding arrangements. This segment also provides comprehensive design and development solutions for creating final medical devices and is involved in the research, development, manufacturing, and sale of minimally invasive technology tailored for precision engineering. Lastly, the Distribution segment handles the supply of various medical products, primarily via its subsidiary, Elemental Healthcare Ltd, and also designs and produces autologous blood products. Surgical Innovations Group plc sells its offerings through a network of independent healthcare distributors, while its own-label products are also distributed through its OEM collaborations.
When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.
-5.4% YoY
YoY Growth Rate
Revenue declining
+37.5% YoY
YoY Growth Rate
EPS growth accelerating
£0/ year
↓ Declining (-100% vs prior year)
0.0% of revenue
Below sector average (18%)
R&D spend declining — could signal cost-cutting or efficiency
Cash flow positive
£813,000 cash & investments
Quarterly Free Cash Flow
→ Burn rate stable
Company generates more cash than it spends — no dilution risk from fundraising
Surgical Innovations Group's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.
The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.
The share count has stayed roughly flat over this period — little dilution or buyback activity.
Diluted shares outstanding: 936.6M (2021) → 932.8M (2025)
Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.
Negative ROIC means the business is losing money on every dollar invested in it.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
FCF margin between 0% and 10%. Some cash from sales, but not a lot.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
